In November, the most popular stories from Interventional News included stories from our latest issue concerning the global lack of interventional radiology (IR) devices for paediatric patients; an international heatmap of IR’s progression to primary specialty; a study which found moral injury to be prevalent among interventional radiologists in the USA; and Ian McCafferty’s (The Radiology Clinic, Birmingham, UK) delivery of the Graham Plant lecture at this year’s British Society of Interventional Radiology (BSIR; 8–10 November 2018, Newport, UK).
1. OncoSil Medical announce first patient treated in PANCOSIL trial
OncoSil Medical, a medical device company focused on localised treatments for patients with locally advanced pancreatic cancer (LAPC) announces the first patient has been treated in the PANCOSIL investigator initiated clinical trial on 28 November 2023.
2. Paediatric interventional radiologists call for intended-for-use device development
“Are we truly upholding the notion that our children are the most valuable good of our society?”
Arguing that the lack of adequate medications and IR devices for children “tells a different story”, Premal Patel, Fernando Gómez Muñoz, and Alessandro Gasparetto survey the current state of paediatric IR and the global device deficit.
3. Inari Medical announces first patient enrolment in PEERLESS II randomised controlled trial
Inari Medical has announced the first patient enrolment in PEERLESS II. This prospective, global, multicentre randomised controlled trial (RCT) compares the outcomes of intermediate-risk acute pulmonary embolism (PE) patients treated with the FlowTriever system against those treated with traditional anticoagulation therapy alone.
4. Moral injury “prevalent” among interventional radiologists in the USA
A recent study concerning moral injury (MI) among interventional radiologists has found that the condition is “prevalent” throughout the field, and has been shown to negatively correlate with quality-of-life (QoL) indicators.
“If we do not take control and if we do not take charge of our own destiny, we will be jeopardising the future sustainability of IR. Maybe I am being a little nihilistic, but I believe that we must start changing things and it needs to happen sooner rather than later.”
Nick Brown, Raman Uberoi, Michael Lee, and Parag Patel discuss the current structure of IR and the value of obtaining specialty status, tracking the field’s burgeoning recognition, concurrent problems and future stability.
6. Interventional approaches to benign bone tumours
Patients diagnosed with benign bone tumours will be relieved to know that these are not malignant, and some tumours will involute spontaneously. However, this natural history can be unpredictable, and tumours can be associated with significant pain, pathologic fracture, or potential for growth and compression of critical structures such as nerves.
7. Fluidx Medical launches new embolic platform for tumour treatment
Fluidx Medical has released information about their new ULTRA embolic platform designed to make therapeutic embolization procedures safer, better, and faster, as the recent press release states.
8. LimFlow announces agreement to be acquired by Inari Medical
LimFlow announced today that it has entered into a definitive agreement to be acquired by Inari Medical.
9. “What does this say about us?”: A call to action for paediatric trauma management
Honoured as the BSIR travelling professor, Ian McCafferty gave the Graham Plant lecture at the annual meeting. Titled ‘Acute trauma intervention: Have we got it right?’
10. Betters Medical receives US FDA clearance for microwave ablation system
Baird Medical, leading microwave ablation (MWA) medical device developer and provider in China, has announced that its subsidiary, Betters Medical, has received clearance from the US Food and Drug Administration (FDA) under Section 510k, to begin marketing its portfolio of MWA systems and disposable MWA needles as regulatory class II devices in the USA.
